MOG and primary cutaneous T-cell non-Hodgkin lymphoma: The MAVORIC phase III trial, comparing MOG and vorinostat in previously treated CTCL, reported that skin rash was present in 24% of patients, with photosensitivity, eczematous dermatitis, erythroderma, and neutrophilic eccrine hidradenitis algo being reported.